Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Novartis |
---|---|
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00171951 |
Cushing's disease is a rare serious condition that is caused by an adrenocorticotropic hormone (ACTH) secreting pituitary adenoma. This study will assess the long-term safety and efficacy of pasireotide in patients with Cushing's disease.
Condition | Intervention | Phase |
---|---|---|
Cushing Disease |
Drug: Pasireotide |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Extension Study to Assess the Safety and Efficacy of Pasireotide in Patients With Cushing's Disease |
Ages Eligible for Study: | 18 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
Exclusion Criteria
Other protocol-defined inclusion / exclusion criteria may apply.
United States, California | |
Los Angeles, California, United States, 90048 | |
United States, Massachusetts | |
Boston, Massachusetts, United States, 02114 | |
United States, Pennsylvania | |
Philadelphia, Pennsylvania, United States, 19104 | |
United States, Wisconsin | |
Milwaukee, Wisconsin, United States, 53215 |
Study Chair: | Novartis | Novartis |
Study ID Numbers: | CSOM230B2208E1 |
Study First Received: | September 13, 2005 |
Last Updated: | August 6, 2007 |
ClinicalTrials.gov Identifier: | NCT00171951 |
Health Authority: | United States: Food and Drug Administration |
Cushing's disease ACTH Cortisol ACTH dependent Cushing's disease |
Hypothalamic Diseases Hydrocortisone Pituitary Diseases Cortisol succinate Cushing Syndrome Adrenal Gland Diseases Endocrine System Diseases |
Central Nervous System Diseases Brain Diseases Adrenocortical Hyperfunction Pituitary ACTH Hypersecretion Endocrinopathy Hydrocortisone acetate |
Hyperpituitarism Nervous System Diseases |